$AMWL

American Well Corp (AMWL): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

American Well Corp (AMWL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K 0001393584 false 0001393584 2026-07-08 2026-07-08 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 08,

Original reporting
Published Jul 14, 2026, 8:39 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 14, 2026, 8:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$AMWL
Neutral
high confidence
Mentioned
$AMWL
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$AMWLNeutralLow
01

Why it matters

This is a governance-structure adjustment with no stated disagreement on operations, policies, or practices, and no change to committee assignments or compensatory arrangements.

02

Market read

Traders may treat this as low-signal governance housekeeping unless the referenced proxy statement contains additional changes.

03

What to watch

The filing points to the April 24, 2026 definitive proxy statement for compensation and committee details; any changes there could matter more than the class rebalancing itself.

Relevance 6/10Novelty 2/10Timing: Filed July 14, 2026, covering a July 8-11 director reclassification event.

Background

The 8-K reports Item 5.02 director/officer changes, specifically Stephen Schlegel’s resignation from Class II and reappointment to Class III to restore approximately equal board class sizes under NYSE listing standards.

Company-level read

Ticker impact

$AMWLNeutralHigh confidence
Context

American Well rebalanced its board by having Stephen Schlegel resign as Class II and be reappointed as Class III director on July 11, 2026.

Expected impact

Low likelihood of sustained price repricing; any reaction is likely limited to governance headline noise.

Evidence & confidence

The filing states the resignation and reappointment were solely to rebalance board classes to meet NYSE listing standards, with no change to committee assignments or compensatory arrangements.

Market effects

Minimal, as this is company-specific governance housekeeping rather than a sector-wide regulatory or operational change.

None indicated.

None indicated.

Counterpoint

Even if framed as administrative, director turnover or reclassification can sometimes precede broader governance or strategic shifts, so traders may watch for follow-on proxy disclosures.

Key entities

  • American Well Corporation

    Company filing the 8-K and rebalancing board classes via director reappointment.

  • Stephen Schlegel

    Reappointed as Class III director after resigning as Class II to rebalance board classes.

  • NYSE listing standards

    Board class sizing requirement referenced as the reason for the reclassification.

Related articles

$AMWLMedAI 8/10

American Well (AMWL) Q2 2026 Earnings Call Transcript

American Well (AMWL) reported Q2 2026 revenue of $52 million, down 26.6% year over year, with subscription revenue of $25.7 million and AMG revenue of $24.4 million. Adjusted EBITDA loss was $1.15 million and net loss was $9.6 million. Full-year guidance was narrowed to $200-$205 million revenue and improved adjusted EBITDA loss to $9-$7 million. The Defense Health Agency issued an intent to award a sole-source contract.

$AMWLMed

American Well Corp (AMWL): AMWELL® ANNOUNCES RESULTS FOR THE Second QUARTER 2026

American Well Corp (AMWL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AMWELL® ANNOUNCES RESULTS FOR THE Second QUARTER 2026 BOSTON, August 4 , 2026 –Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the second quarter ended June 30, 2026

$PCVXMedAI 8/10

Vaxcyte, Inc. (PCVX) Prices ~$1.0B Equity And 1.50% Converts

Vaxcyte, Inc. (PCVX) raised ~$1.0B through a share offering, warrant sales, and convertible notes. The company issued 7.41M shares at $64, 400K pre-funded warrants, and $500M of 1.50% convertible notes due 2032. Proceeds will fund Phase 3 trials, scale-up, and U.S. adult launch prep, according to the company.